Literature DB >> 19825961

Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype.

Shuji Ogino1, Katsuhiko Nosho, Natsumi Irahara, Jeffrey A Meyerhardt, Yoshifumi Baba, Kaori Shima, Jonathan N Glickman, Cristina R Ferrone, Mari Mino-Kenudson, Noriko Tanaka, Glenn Dranoff, Edward L Giovannucci, Charles S Fuchs.   

Abstract

PURPOSE: Host immune response to tumor may be an important prognostic factor for colon cancer patients. However, little is known on prognostic significance of histopathologic lymphoid reaction to tumor, independent of the number of lymph nodes examined and tumoral molecular alterations, including microsatellite instability (MSI) and the CpG island methylator phenotype (CIMP), both of which are associated with lymphocytic reaction and clinical outcome. EXPERIMENTAL
DESIGN: Using 843 colorectal cancer patients in two independent prospective cohorts, we examined patient prognosis in relation to four components of lymphocytic reaction (i.e., Crohn's-like reaction, peritumoral reaction, intratumoral periglandular reaction, and tumor-infiltrating lymphocytes) and overall lymphocytic score (0-12). CIMP was determined using eight markers including CACNA1G, CDKN2A (p16), CRABP1, IGF2, MLH1, NEUROG1, RUNX3, and SOCS1. Cox proportional hazard models computed hazard ratio for mortality, adjusted for covariates including tumor stage, body mass index, lymph node count, KRAS, BRAF, p53, cyclooxygenase-2 (PTGS2), MSI, CIMP, and LINE-1 methylation.
RESULTS: Increasing overall lymphocytic reaction score including tumor-infiltrating lymphocytes was associated with a significant improvement in colorectal cancer-specific and overall survival (log-rank P < 0.003). These findings remained significant (adjusted hazard ratio estimates, 0.49-0.71; P(trend) < 0.009) in multivariate models that adjusted for covariates, including body mass index, MSI, CIMP, LINE-1 hypomethylation, and cyclooxygenase-2. The beneficial effect of tumoral lymphocytic reaction was consistent across strata of clinical, pathologic, and molecular characteristics.
CONCLUSIONS: Lymphocytic reactions to tumor were associated with improved prognosis among colorectal cancer patients, independent of lymph node count and other clinical, pathologic, and molecular characteristics.

Entities:  

Mesh:

Year:  2009        PMID: 19825961      PMCID: PMC2771425          DOI: 10.1158/1078-0432.CCR-09-1438

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  50 in total

1.  Effector memory T cells, early metastasis, and survival in colorectal cancer.

Authors:  Franck Pagès; Anne Berger; Matthieu Camus; Fatima Sanchez-Cabo; Anne Costes; Robert Molidor; Bernhard Mlecnik; Amos Kirilovsky; Malin Nilsson; Diane Damotte; Tchao Meatchi; Patrick Bruneval; Paul-Henri Cugnenc; Zlatko Trajanoski; Wolf-Herman Fridman; Jérôme Galon
Journal:  N Engl J Med       Date:  2005-12-22       Impact factor: 91.245

2.  Increasing negative lymph node count is independently associated with improved long-term survival in stage IIIB and IIIC colon cancer.

Authors:  Paul M Johnson; Geoff A Porter; Rocco Ricciardi; Nancy N Baxter
Journal:  J Clin Oncol       Date:  2006-08-01       Impact factor: 44.544

3.  CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer.

Authors:  Daniel J Weisenberger; Kimberly D Siegmund; Mihaela Campan; Joanne Young; Tiffany I Long; Mark A Faasse; Gyeong Hoon Kang; Martin Widschwendter; Deborah Weener; Daniel Buchanan; Hoey Koh; Lisa Simms; Melissa Barker; Barbara Leggett; Joan Levine; Myungjin Kim; Amy J French; Stephen N Thibodeau; Jeremy Jass; Robert Haile; Peter W Laird
Journal:  Nat Genet       Date:  2006-06-25       Impact factor: 38.330

4.  Correlation of pathologic features with CpG island methylator phenotype (CIMP) by quantitative DNA methylation analysis in colorectal carcinoma.

Authors:  Shuji Ogino; Robert D Odze; Takako Kawasaki; Mohan Brahmandam; Gregory J Kirkner; Peter W Laird; Massimo Loda; Charles S Fuchs
Journal:  Am J Surg Pathol       Date:  2006-09       Impact factor: 6.394

5.  CpG island methylator phenotype-low (CIMP-low) in colorectal cancer: possible associations with male sex and KRAS mutations.

Authors:  Shuji Ogino; Takako Kawasaki; Gregory J Kirkner; Massimo Loda; Charles S Fuchs
Journal:  J Mol Diagn       Date:  2006-11       Impact factor: 5.568

6.  Combined analysis of COX-2 and p53 expressions reveals synergistic inverse correlations with microsatellite instability and CpG island methylator phenotype in colorectal cancer.

Authors:  Shuji Ogino; Mohan Brahmandam; Takako Kawasaki; Gregory J Kirkner; Massimo Loda; Charles S Fuchs
Journal:  Neoplasia       Date:  2006-06       Impact factor: 5.715

7.  CpG island methylator phenotype (CIMP) of colorectal cancer is best characterised by quantitative DNA methylation analysis and prospective cohort studies.

Authors:  S Ogino; M Cantor; T Kawasaki; M Brahmandam; G J Kirkner; D J Weisenberger; M Campan; P W Laird; M Loda; C S Fuchs
Journal:  Gut       Date:  2006-01-11       Impact factor: 23.059

8.  Type, density, and location of immune cells within human colorectal tumors predict clinical outcome.

Authors:  Jérôme Galon; Anne Costes; Fatima Sanchez-Cabo; Amos Kirilovsky; Bernhard Mlecnik; Christine Lagorce-Pagès; Marie Tosolini; Matthieu Camus; Anne Berger; Philippe Wind; Franck Zinzindohoué; Patrick Bruneval; Paul-Henri Cugnenc; Zlatko Trajanoski; Wolf-Herman Fridman; Franck Pagès
Journal:  Science       Date:  2006-09-29       Impact factor: 47.728

9.  Lymph node counts, rates of positive lymph nodes, and patient survival for colon cancer surgery in Ontario, Canada: a population-based study.

Authors:  Luke Bui; Eddy Rempel; Dana Reeson; Marko Simunovic
Journal:  J Surg Oncol       Date:  2006-05-01       Impact factor: 3.454

10.  Will Rogers revisited: prospective observational study of survival of 3592 patients with colorectal cancer according to number of nodes examined by pathologists.

Authors:  S George; J Primrose; R Talbot; J Smith; M Mullee; D Bailey; C du Boulay; H Jordan
Journal:  Br J Cancer       Date:  2006-09-12       Impact factor: 7.640

View more
  174 in total

Review 1.  Tumour-infiltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review.

Authors:  Katsuhiko Nosho; Yoshifumi Baba; Noriko Tanaka; Kaori Shima; Marika Hayashi; Jeffrey A Meyerhardt; Edward Giovannucci; Glenn Dranoff; Charles S Fuchs; Shuji Ogino
Journal:  J Pathol       Date:  2010-12       Impact factor: 7.996

Review 2.  Microsatellite instability in colorectal cancer.

Authors:  C Richard Boland; Ajay Goel
Journal:  Gastroenterology       Date:  2010-06       Impact factor: 22.682

Review 3.  Dual roles for immunity in gastrointestinal cancers.

Authors:  Cristina Ferrone; Glenn Dranoff
Journal:  J Clin Oncol       Date:  2010-07-19       Impact factor: 44.544

4.  MicroRNA MIR21 and T Cells in Colorectal Cancer.

Authors:  Kosuke Mima; Reiko Nishihara; Jonathan A Nowak; Sun A Kim; Mingyang Song; Kentaro Inamura; Yasutaka Sukawa; Atsuhiro Masuda; Juhong Yang; Ruoxu Dou; Katsuhiko Nosho; Hideo Baba; Edward L Giovannucci; Michaela Bowden; Massimo Loda; Marios Giannakis; Adam J Bass; Glenn Dranoff; Gordon J Freeman; Andrew T Chan; Charles S Fuchs; Zhi Rong Qian; Shuji Ogino
Journal:  Cancer Immunol Res       Date:  2015-09-29       Impact factor: 11.151

5.  Tumor SQSTM1 (p62) expression and T cells in colorectal cancer.

Authors:  Keisuke Kosumi; Yohei Masugi; Juhong Yang; Zhi Rong Qian; Sun A Kim; Wanwan Li; Yan Shi; Annacarolina da Silva; Tsuyoshi Hamada; Li Liu; Mancang Gu; Tyler S Twombly; Yin Cao; David A Barbie; Katsuhiko Nosho; Hideo Baba; Wendy S Garrett; Jeffery A Meyerhardt; Edward L Giovannucci; Andrew T Chan; Charles S Fuchs; Shuji Ogino; Reiko Nishihara
Journal:  Oncoimmunology       Date:  2017-01-31       Impact factor: 8.110

6.  Aspirin Use and Colorectal Cancer Survival According to Tumor CD274 (Programmed Cell Death 1 Ligand 1) Expression Status.

Authors:  Tsuyoshi Hamada; Yin Cao; Zhi Rong Qian; Yohei Masugi; Jonathan A Nowak; Juhong Yang; Mingyang Song; Kosuke Mima; Keisuke Kosumi; Li Liu; Yan Shi; Annacarolina da Silva; Mancang Gu; Wanwan Li; NaNa Keum; Xuehong Zhang; Kana Wu; Jeffrey A Meyerhardt; Edward L Giovannucci; Marios Giannakis; Scott J Rodig; Gordon J Freeman; Daniel Nevo; Molin Wang; Andrew T Chan; Charles S Fuchs; Reiko Nishihara; Shuji Ogino
Journal:  J Clin Oncol       Date:  2017-04-13       Impact factor: 44.544

7.  Association Between Inflammatory Diet Pattern and Risk of Colorectal Carcinoma Subtypes Classified by Immune Responses to Tumor.

Authors:  Li Liu; Reiko Nishihara; Zhi Rong Qian; Fred K Tabung; Daniel Nevo; Xuehong Zhang; Mingyang Song; Yin Cao; Kosuke Mima; Yohei Masugi; Yan Shi; Annacarolina da Silva; Tyler Twombly; Mancang Gu; Wanwan Li; Tsuyoshi Hamada; Keisuke Kosumi; Kentaro Inamura; Jonathan A Nowak; David A Drew; Paul Lochhead; Katsuhiko Nosho; Kana Wu; Molin Wang; Wendy S Garrett; Andrew T Chan; Charles S Fuchs; Edward L Giovannucci; Shuji Ogino
Journal:  Gastroenterology       Date:  2017-09-01       Impact factor: 22.682

8.  Analysis of PD1, PDL1, PDL2 expression and T cells infiltration in 1014 gastric cancer patients.

Authors:  Xiaofang Xing; Jianping Guo; Guangyu Ding; Bo Li; Bin Dong; Qin Feng; Shen Li; Jian Zhang; Xiaomin Ying; Xiaojing Cheng; Ting Guo; Hong Du; Ying Hu; Tao Zhou; Xiaohong Wang; Lin Li; Qingda Li; Meng Xie; Liting Li; Xiangyu Gao; Fei Shan; Ziyu Li; Xianzi Wen; Jiping Wang; Jiafu Ji
Journal:  Oncoimmunology       Date:  2017-12-21       Impact factor: 8.110

9.  Tumor-infiltrating B cells come into vogue.

Authors:  Michael Linnebacher
Journal:  World J Gastroenterol       Date:  2013-01-07       Impact factor: 5.742

Review 10.  Immune Therapy in GI Malignancies: A Review.

Authors:  Judy Wang; Kim A Reiss; Rina Khatri; Elizabeth Jaffee; Dan Laheru
Journal:  J Clin Oncol       Date:  2015-04-27       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.